EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identifying prognostic targets in metastatic prostate cancer beyond AR

Emily Feng, Eric Feng iD, Tracy Berg, Isabella S Nguyen, Lilac G Nguyen, William Chen, Meng Zhang, David Quigley, Marina Sharifi, Haolong Li, Ilsa Coleman, Peter S Nelson iD und 2 weitere

FEBS Open Bio · 2025

DOI: 10.1002/2211-5463.70059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, 2025. Verfasst von Emily Feng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of California San Francisco, CA, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Receptors, Androgen. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DoD, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genome‐wide screens using CRISPR/RNAi can identify new therapeutic vulnerabilities in prostate cancer. In this study, we combine DepMap functional screen data with a large gene expression database ( N = 1012) and clinical outcomes to identify potentially druggable targets. Eight genes ( CYC , CYP51A1 , DHFR , EBP , KIF15 , PPM1D , SQLE , and UMPS ) demonstrated strong dependency in cell lines and were also associated with worse prognosis clinically, representing potential therapeutic targets in metastatic prostate cancer. Four of these ( DHFR , EBP , KIF15 , and PPM1D ) demonstrated higher expression in neuroendocrine prostate cancer. Furthermore, all but one ( KIF15 ) were not significantly decreased from pretreatment to posttreatment, suggesting that they may remain targetable postabiraterone therapy. All eight genes showed evidence of protein expression in prostate cancers or cell lines. These potentially druggable targets associated with prostate cancer cell line dependency and worse clinical outcomes have also demonstrated literature support as potential targets, supporting further research into their potential clinical relevance as therapeutic targets in prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsReceptors, AndrogenHumansMalePrognosisCell Line, TumorGene Expression Regulation, NeoplasticNeoplasm MetastasisBiomarkers, Tumor

Stichwörter der Autor:innen

DepMapclinicogenomicprostate cancer

Substanzen

Receptors, AndrogenBiomarkers, TumorAR protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of California San Francisco, CA, USA.
  • Department of Human Oncology, University of Wisconsin, Madison, WI, USA.
  • Department of Medicine, University of Wisconsin, Madison, WI, USA.
  • Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Lund University, Sweden.

ORCID-Profile: Eric Feng, Peter S Nelson, Martin Sjöström, Shuang G Zhao

Förderung

  • DoD
  • NCI NIH HHS
  • NIH HHS
  • Institute for Prostate Cancer Research
  • Prostate Cancer Foundation
  • Swedish Cancer Society (Cancerfonden)
  • Swedish Prostate Cancer Foundation (Prostatacancerförbundet)
  • Hjelms Stiftelse för Medicinsk Forskning

Zitieren

APA

Feng, E., Feng, E., Berg, T., Nguyen, I. S., Nguyen, L. G., Chen, W., Zhang, M., Quigley, D., Sharifi, M., Li, H., Coleman, I., Nelson, P. S., Sjöström, M., & Zhao, S. G. (2025). Identifying prognostic targets in metastatic prostate cancer beyond AR. FEBS Open Bio. https://doi.org/10.1002/2211-5463.70059

Vancouver

Feng E, Feng E, Berg T, Nguyen IS, Nguyen LG, Chen W, et al. Identifying prognostic targets in metastatic prostate cancer beyond AR. FEBS Open Bio. 2025. doi:10.1002/2211-5463.70059

BibTeX
@article{Feng2025,
  author = {Feng, Emily and Feng, Eric and Berg, Tracy and Nguyen, Isabella S and Nguyen, Lilac G and Chen, William and Zhang, Meng and Quigley, David and Sharifi, Marina and Li, Haolong and Coleman, Ilsa and Nelson, Peter S and Sjöström, Martin and Zhao, Shuang G},
  title = {Identifying prognostic targets in metastatic prostate cancer beyond AR},
  journal = {FEBS Open Bio},
  year = {2025},
  doi = {10.1002/2211-5463.70059}
}
Kostenlos starten →